Evotec SE
EVTGermany
22 filed reports · 245 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
22 reports · Sep 2018 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Half YearBundesanzeiger | 6 | 625 | Jun 2021 to Jun 2026 |
| Q3Bundesanzeiger | 6 | 565 | Sep 2018 to Sep 2025 |
| AnnualBundesanzeiger | 5 | 375 | Dec 2021 to Dec 2025 |
| Q1Bundesanzeiger | 5 | 296 | Mar 2021 to Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | half year | Jun 30, 2026 | Jun 30, 2026 | 100 | Open |
| FY2026 Q1 | q1 | Mar 31, 2026 | Mar 31, 2026 | 79 | Open |
| FY2025 | annual | Dec 31, 2025 | Apr 8, 2026 | 73 | Open |
| FY2025 Q3 | q3 | Sep 30, 2025 | Sep 30, 2025 | 97 | Open |
| FY2025 Q2 | half year | Jun 30, 2025 | Jun 30, 2025 | 108 | Open |
| FY2025 Q1 | q1 | Mar 31, 2025 | Mar 31, 2025 | 65 | Open |
| FY2024 | annual | Dec 31, 2024 | Apr 17, 2025 | 95 | Open |
| FY2024 Q3 | q3 | Sep 30, 2024 | Sep 30, 2024 | 109 | Open |
| FY2024 Q2 | half year | Jun 30, 2024 | Jun 30, 2024 | 110 | Open |
| FY2024 Q1 | q1 | Mar 31, 2024 | Mar 31, 2024 | 75 | Open |
| FY2023 | annual | Dec 31, 2023 | Dec 31, 2023 | 96 | Open |
| FY2023 Q3 | q3 | Sep 30, 2023 | Sep 30, 2023 | 94 | Open |
Financial data
245 concepts · 1,861 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS226 concepts · 1,730 facts · Sep 2018 to Jun 2026
- Income Tax Expense (Benefit)31 · Mar 2021 to Dec 2025
- R&D Expense31 · Sep 2018 to Jun 2026
- Contract liabilities29 · Sep 2018 to Jun 2026
- Provisions29 · Sep 2018 to Jun 2026
- Cost of Revenue28 · Sep 2018 to Jun 2026
- Gross Profit28 · Sep 2018 to Jun 2026
- Revenue28 · Sep 2018 to Jun 2026
- SG&A Expense28 · Sep 2018 to Jun 2026
- Weighted average shares outstanding28 · Sep 2018 to Jun 2026
- Income before taxes26 · Mar 2021 to Sep 2025
- Operating Income26 · Sep 2018 to Jun 2026
- — Other operating income26 · Sep 2018 to Jun 2026
- Total non-operating income (expense)24 · Sep 2018 to Sep 2025
- — Share of the result of associates accounted for using the equity method23 · Jun 2021 to Sep 2025
- — Other operating expense22 · Mar 2021 to Sep 2025
- Total operating income (expense)22 · Mar 2021 to Sep 2025
- Net Income21 · Sep 2018 to Jun 2026
- Interest20 · Dec 2022 to Dec 2025
- — Measurement result from investments18 · Mar 2022 to Sep 2025
- Net cash provided by (used in) financing activities18 · Mar 2021 to Jun 2026
- Net income per share (basic)18 · Mar 2021 to Sep 2025
- Net income per share (diluted)18 · Mar 2021 to Sep 2025
- — Other non-operating income (expense), net18 · Jun 2021 to Sep 2025
- Inventory17 · Sep 2018 to Jun 2026
Segment18 concepts · 130 facts · Sep 2018 to Jun 2026
- Gross Profit20 · Sep 2018 to Jun 2026
- Revenue18 · Jun 2021 to Jun 2026
- SG&A Expense14 · Sep 2018 to Mar 2025
- R&D Expense12 · Jun 2021 to Jun 2026
- Net Income10 · Dec 2023 to Dec 2024
- Operating Income9 · Jun 2021 to Jun 2026
- Cost of Revenue8 · Jun 2021 to Jun 2026
- — Other operating income7 · Sep 2018 to Jun 2026
- Other operating income (expenses), net6 · Sep 2021 to Sep 2023
- Reorganization costs5 · Sep 2024 to Jun 2026
- Adjusted EBITDA4 · Sep 2018 to Jun 2026
- Other operating income4 · Mar 2026 to Jun 2026
- Other operating expense 4)3 · Sep 2024 to Mar 2025
- External revenues2 · Sep 2018
- Impairments of intangible assets2 · Sep 2018 to Sep 2023
- Net operating income (loss)2 · Sep 2023
- Other operating expenses2 · Sep 2018
- plus change in contingent consideration (earn-out)2 · Jun 2021
KPI1 concepts · 1 facts · Mar 2025
- Gross Profit1 · Mar 2025
Segments
130 factsFigures broken down by business line, region, product or another axis the company reports on.
Operating segment6 members · 116 facts
- EVT Execute35 · Sep 2018 to Sep 2023
- EVT Innovate35 · Sep 2018 to Sep 2023
- Shared R&D14 · Jun 2024 to Mar 2025
- D&PD13 · Mar 2026 to Jun 2026
- Just - Evotec Biologics10 · Sep 2024 to Mar 2025
- JEB9 · Mar 2026 to Jun 2026
Associate company8 members · 14 facts
- Quantro Therapeutics GmbH4 · Dec 2023 to Dec 2024
- Centauri Therapeutics GmbH2 · Dec 2023
- Centauri Therapeutics Ltd2 · Dec 2024
- Dark Blue Therapeutics Ltd2 · Dec 2023 to Dec 2024
- Autobahn Labs LLC1 · Dec 2023
- Curexsys GmbH1 · Dec 2023
- EIR Biotherapies1 · Dec 2024
- Topas Therapeutics GmbH1 · Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.